Individual patient data meta-analysis of paclitaxel-coated balloons vs. drug-eluting stents for small-vessel coronary artery disease: the ANDROMEDA study.
Fezzi S, Giacoppo D, Fahrni G, Latib A, Alfonso F, Colombo A, Mahfoud F, Scheller B, Jeger R, Cortese B.
Eur Heart J. 2025 May 2;46(17):1586-1599. doi: 10.1093/eurheartj/ehaf002.
Orbital atherectomy versus balloon angioplasty before drug-eluting stent implantation in severely calcified lesions eligible for both treatment strategies (ECLIPSE): a multicentre, open-label, randomised trial.
Kirtane AJ, Généreux P, Lewis B, Shlofmitz RA, Dohad S, Choudary J, Dahle T, Pineda AM, Shunk K, Maehara A, Popma A, Redfors B, Ali ZA, Krucoff M, Armstrong E, Kandzari DE, O'Neill W, Kraemer C, Stiefel KM, Jones DE, Chambers J, Stone GW; ECLIPSE Investigators.
Lancet. 2025 Apr 12;405(10486):1240-1251. doi: 10.1016/S0140-6736(25)00450-7. Epub 2025 Mar 30.
Feasibility and Clinical Outcomes of 48 mm Drug-Eluting Stents in the Management of Patients With Coronary Artery Disease.
El Amrawy AM, Loutfi MI, El Tahan SM, Ayad SW.
J Invasive Cardiol. 2021 Dec;33(12):E960-E967. doi: 10.25270/jic/20.00660. Epub 2021 Nov 24.
Multiple overlapping drug-eluting stents to treat diffuse disease of the left anterior descending coronary artery.
Tsagalou E, Chieffo A, Iakovou I, Ge L, Sangiorgi GM, Corvaja N, Airoldi F, Montorfano M, Michev I, Colombo A.
J Am Coll Cardiol. 2005 May 17;45(10):1570-3. doi: 10.1016/j.jacc.2005.01.049.
Mid-term clinical outcomes of new generation drug-eluting stents for treatment of diffuse coronary artery disease.
Çoner A, Çiçek D, Akıncı S, Balcıoğlu S, Altın C, Müderrisoğlu H.
Turk Kardiyol Dern Ars. 2018 Dec;46(8):659-666. doi: 10.5543/tkda.2018.10.5543/tkda.2018.62678.
Lifetime management of severely calcified coronary lesions: the treatment algorithm focused on the shape of calcification.
Sakakura K, Jinnouchi H, Taniguchi Y, Yamamoto K, Fujita H.
Cardiovasc Interv Ther. 2023 Oct;38(4):375-380. doi: 10.1007/s12928-023-00950-x. Epub 2023 Aug 5.
Prognostic value of plasma pentraxin-3 levels in patients with stable coronary artery disease after drug-eluting stent implantation.
Haibo L, Xiaofang G, Chunming W, Jie Y, Guozhong C, Limei Z, Yong C, Yu F, Yingchun B, Wangjun Y, Junbo G.
Mediators Inflamm. 2014;2014:963096. doi: 10.1155/2014/963096. Epub 2014 Nov 24.
Impact of coronary anatomy and stenting technique on long-term outcome after drug-eluting stent implantation for unprotected left main coronary artery disease.
Tiroch K, Mehilli J, Byrne RA, Schulz S, Massberg S, Laugwitz KL, Vorpahl M, Seyfarth M, Kastrati A; ISAR-LEFT MAIN Study Investigators.
JACC Cardiovasc Interv. 2014 Jan;7(1):29-36. doi: 10.1016/j.jcin.2013.08.013. Epub 2013 Dec 11.
Identifying the Incidence, Predictors, Outcomes, and Prevention of Stent Thrombosis (ST) in Post-percutaneous Coronary Revascularization Patients With Drug-Eluting Stents (DES): A Systematic Review.
Sohail M, Patel P, Midha S, Shukla S, Dhamija D, Bello AO, Khan AA, Gutlapalli SD, Venugopal S.
Cureus. 2023 Sep 13;15(9):e45150. doi: 10.7759/cureus.45150. eCollection 2023 Sep.
Comparison of drug-eluting stents and bare-metal stents for the treatment of unprotected left main coronary artery disease in acute coronary syndromes.
Tamburino C, Di Salvo ME, Capodanno D, Palmerini T, Sheiban I, Margheri M, Vecchi G, Sangiorgi G, Piovaccari G, Bartorelli A, Briguori C, Ardissino D, Di Pede F, Ramondo A, Inglese L, Petronio AS, Bolognese L, Benassi A, Palmieri C, Filippone V, De Servi S.
Am J Cardiol. 2009 Jan 15;103(2):187-93. doi: 10.1016/j.amjcard.2008.08.059. Epub 2008 Oct 30.
